Clinical Trials
- Lung Cancer
A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy
- Date10/20/2020
- Lung Cancer
A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN) Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
- Date07/31/2020
- Cancer, Gynecological Cancers, Head and Neck Cancers, Lung Cancer, Sarcoma Cancers
A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors
- Date08/23/2021
- Lung Cancer
A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)
- Date07/14/2020
- Lung Cancer
A Phase 2 Study of Poziotinib in Patients With Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, With EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)
- Date08/06/2020
- Lung Cancer, Melanoma
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144 or LN-145) in Patients With Solid Tumors
- Date07/13/2021
- Lung Cancer
A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Participants With Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)
- Date06/29/2020
- Bladder Cancer, Lung Cancer, Melanoma, Other Cancers
A Phase I/Ib Study of APX005M in Combination With Nivolumab and Cabiralizumab in Patients With Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma Whose Disease Has Progressed on Anti-PD- 1/PD-L1 Therapy
- Date09/08/2020
- Brain and Other Nervous System Cancers, Lung Cancer, Melanoma
A Phase II Trial of Pembrolizumab Plus Bevacizumab in Patients With Metastatic Melanoma or Non-small Cell Lung Cancer With Untreated Brain Metastases
- Ages18 years and older
- GenderBoth
- Date09/22/2020
- Lung Cancer
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
- Date07/14/2020